Xarelto (rivaroxaban) / J&J 
Welcome,         Profile    Billing    Logout  
 97 Diseases   247 Trials   247 Trials   14602 News 


«12...146147148149150151152153154155156...170171»
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J, Pradaxa (dabigatran etexilate) / Boehringer Ingelheim, Eliquis (apixaban) / BMS
    Clinical, Journal:  Evaluation of a pharmacist-led outpatient direct oral anticoagulant service. (Pubmed Central) -  May 24, 2019   
    A pharmacist-led DOAC service increased appropriate dosing of DOACs at baseline and follow up as well as patient adherence to therapy.
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J, Pradaxa (dabigatran etexilate) / Boehringer Ingelheim, Eliquis (apixaban) / BMS
    Clinical, Journal:  Issues of antithrombotic therapy in ACS patients with atrial fibrillation (Pubmed Central) -  May 24, 2019   
    Concerning rivaroxaban, the results of two phase III, randomized and controlled trials confirm the non-inferiority of this drug compared to standard therapy (enoxaparin/warfarin) for the treatment of patients with pulmonary embolism (EINSTEIN PE Study) or deep vein thrombosis (EINSTEIN DVT Study) in terms of both efficacy and safety, supporting its use as an effective therapeutic option for these disorders. The review analyzed current ideas on prevalence and clinical significance of atrial fibrillation following acute coronary syndrome; described modern approaches to administration of antithrombotic therapy; and addressed available clinical studies on the treatment with warfarin and new oral anticoagulants as a part of combination antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome.
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J
    Clinical, Journal:  Anticoagulant Therapy in Elderly Patients With Atrial Fibrillation (Pubmed Central) -  May 24, 2019   
    Further investigation is needed to understand optimal anticoagulation strategies in patients with AF and cancer. Is this paper discuss problems of selection of anticoagulant therapy in elderly patients with atrial fibrillation, use of unreasonably low doses of anticoagulants, their risks and adherence to therapy is discussed in the paper.
  • ||||||||||  Enrollment open, HEOR, Real-world evidence, Real-world:  Non-interventional, Retrospective Cohort Study to Explore OAC Treatment in Korea (clinicaltrials.gov) -  May 23, 2019   
    P=N/A,  N=1, Recruiting, 
    Is this paper discuss problems of selection of anticoagulant therapy in elderly patients with atrial fibrillation, use of unreasonably low doses of anticoagulants, their risks and adherence to therapy is discussed in the paper. Active, not recruiting --> Recruiting
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Hakko Kirin, Mitsubishi Tanabe
    Journal:  Predictors of Chronic Thromboembolic Pulmonary Hypertension. (Pubmed Central) -  May 22, 2019   
    Of concomitant diseases, significant risk factors for development of CTEPH were grade 3 hypertensive disease, diabetes mellitus, post-infarction cardiosclerosis. On the other hand, age, gender, degree of severity at the time of admission, presence of infarction pneumonia, surgical prevention of recurrent pulmonary embolism, number of pregnancies and deliveries, history of trauma and malignancies, cardiac arrhythmias produced no significant impact on the development of CTEPH.
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo, Fragmin (dalteparin sodium) / Pfizer, Eisai
    Enrollment status, Trial completion date, Trial primary completion date:  Vascular Boot Warming Program After Acute Deep Vein Thrombosis (DVT)  (clinicaltrials.gov) -  May 20, 2019   
    P=N/A,  N=30, Recruiting, 
    Completed --> Terminated; Imbalance in the efficacy and safety endpoints between treatment arms in favor of comparator Enrolling by invitation --> Recruiting | Trial completion date: Dec 2018 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2020
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J, Pradaxa (dabigatran etexilate) / Boehringer Ingelheim, Eliquis (apixaban) / BMS
    Clinical, Journal:  The Choice of Anticoagulant Therapy in Patients With Non-Valvular Atrial Fibrillation and Chronic Kidney Disease (Pubmed Central) -  May 17, 2019   
    The absence of RCT data complicates the choice of anticoagulant therapy in patients with CKD on hemodialysis, although the NOAC approved by the Office of Quality Control Food and Drug US drugs (FDA) for the use of patients in this category. According to the instruction drugs rivaroxaban and apixaban are allowed to use in patients with end-stage CKD with creatinine clearance not less than 15 ml/min.
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J, Savaysa (edoxaban) / Daiichi Sankyo, Eliquis (apixaban) / BMS
    Clinical, Review, Journal:  Efficacy and safety of Xa inhibitors for the treatment of cancer-associated venous thromboembolism. (Pubmed Central) -  May 17, 2019   
    Other patient, treatment, and cancer characteristics may also be associated with a higher risk of major bleeding. Therefore, when assessing the appropriateness of Xa inhibitors for the treatment of CAT, the clinician must take into consideration the known interactions of these drugs, the individualized bleeding risk, and the patient's preferences, in order to make the best possible anticoagulation therapy recommendation.
  • ||||||||||  PK/PD data, Review, Journal:  Pharmacokinetics and Pharmacodynamics of Oral Anticoagulants used in Atrial Fibrillation. (Pubmed Central) -  May 16, 2019   
    Despite the wealth of information available, particularly on VKAs, our knowledge on the pharmacology responsible for certain drug effects and inter-individual variations is still limited. Increasing efforts are being made to uncover these and includes focus on pharmacogenomics and drug transporter proteins.
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J
    Clinical, Journal:  Rivaroxaban-related acute kidney injury in a patient with IgA vasculitis. (Pubmed Central) -  May 14, 2019   
    To the best of our knowledge, this is the first case of direct oral anticoagulant (DOAC)-related AKI in systemic vasculitis. During DOAC therapy, close monitoring of a patient's urinalysis results and their renal function may be required for patients with systemic vasculitis to avoid AKI.
  • ||||||||||  rivaroxaban / Generic mfg.
    Enrollment closed, Trial completion date, Trial primary completion date:  RIVER: Rivaroxaban Evaluation in Real Life Settings (clinicaltrials.gov) -  May 10, 2019   
    P=N/A,  N=5000, Active, not recruiting, 
    No abstract available Recruiting --> Active, not recruiting | Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> May 2019
  • ||||||||||  rivaroxaban / Generic mfg., warfarin / Generic mfg.
    Trial completion, Enrollment change:  CALLIPER: Clinical Outcomes Among Non-valvular Atrial Fibrillation Patients With Renal Dysfunction (clinicaltrials.gov) -  May 10, 2019   
    P=N/A,  N=16000, Completed, 
    Recruiting --> Active, not recruiting | Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> May 2019 Active, not recruiting --> Completed | N=11000 --> 16000
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J
    Clinical, Journal:  Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis. (Pubmed Central) -  May 7, 2019   
    P=N/A
    (A Study Exploring Two Strategies of Rivaroxaban [JNJ39039039; BAY-59-7939] and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention [PIONEER AF-PCI]; NCT01830543). Rivaroxaban was effective and safe in acute HCV-related non-neoplastic PVT with improved short-term survival rate; ClinicalTrials.gov Identifier: NCT03201367.
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J
    Clinical, Journal:  Lesson of the month 2: Pulmonary embolism in a patient on rivaroxaban and concurrent carbamazepine. (Pubmed Central) -  May 7, 2019   
    This case report highlights the importance of reviewing patient medications when considering anticoagulants and the need to raise awareness of these drug interactions among clinicians when making their choice of anticoagulation. It also reinforces the current lack of evidence for use of DOACs in patients with solid organ malignancies.
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J
    Journal:  A post-thrombotic pelvic congestion syndrome (Pubmed Central) -  May 7, 2019   
    Management of pelvic congestion syndrome secondary to post-thrombotic lesions must take into account its pathophysiology. It involves iliac venous angioplasty with stent placement in combination with antithrombotic therapy, which modalities remain to be specified in long-term follow-up.
  • ||||||||||  rivaroxaban / Generic mfg.
    Trial completion, Trial completion date, Trial primary completion date:  Rivaroxaban Hypericum Trial (clinicaltrials.gov) -  May 7, 2019   
    P1,  N=12, Completed, 
    It involves iliac venous angioplasty with stent placement in combination with antithrombotic therapy, which modalities remain to be specified in long-term follow-up. Recruiting --> Completed | Trial completion date: Oct 2019 --> Apr 2019 | Trial primary completion date: Sep 2019 --> Apr 2019